Loading
TYRA-300 is an experimental small-molecule drug from Tyra Biosciences in phase 2 trials for bladder & urothelial cancer, aimed at FGFR2.
TYRA-300 is a small-molecule drug developed by Tyra Biosciences. Its target is FGFR2 (the sponsor names FGFR3). The sponsor states: TYRA-300 is an oral, FGFR3-selective tyrosine kinase inhibitor that targets tumours containing activating FGFR3 gene alterations. ClinicalTrials.gov describes the intervention as: TYRA-300 is an oral, novel potent FGFR 3-selective tyrosine kinase inhibitor that targets tumours that contain activating gene alterations of FGFR3. It is the investigational product in 2 recruiting or active industry-led phase 2 and phase 3 interventional cancer trials, in bladder & urothelial cancer. The largest, NCT05544552, plans to enrol 310 participants with primary completion expected 2026-11. Status reflects the highest phase registered on ClinicalTrials.gov; no efficacy results are recorded here.
TYRA-300 is an oral, FGFR3-selective tyrosine kinase inhibitor that targets tumours containing activating FGFR3 gene alterations. Connects to FGFR2.
1.TYRA-300 slips into a pocket on FGFR2.
Country and place are remembered in this browser only. A postcode is sent to OpenStreetMap's Nominatim service to find coordinates when you press the button; nothing else leaves your device.
Query for this drug: (TITLE:"TYRA-300" OR ABSTRACT:"TYRA-300") AND (cancer OR tumor OR tumour OR oncology OR carcinoma OR lymphoma OR leukemia OR leukaemia OR myeloma OR sarcoma OR melanoma OR glioma). Results are unfiltered search hits about TYRA-300, not a curated reading list.
Shares FGFR2, Bladder & urothelial cancer and the tag pipeline.
Shares FGFR2, Bladder & urothelial cancer and the tag pipeline.
Shares FGFR2 and the tag pipeline.
Shares FGFR2 and the tag pipeline.
Shares Bladder & urothelial cancer and the tag pipeline.
Shares FGFR2 and the tag pipeline.
Shares FGFR2 and the tag pipeline.
Shares Bladder & urothelial cancer and the tag pipeline.